Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Cash from Operations (2024 - 2025)

Beta Bionics (BBNX) has disclosed Cash from Operations for 2 consecutive years, with 8627000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 39.58% to 8627000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 50925000.0 through Dec 2025, down 5.49% year-over-year, with the annual reading at 50925000.0 for FY2025, 5.49% down from the prior year.
  • Cash from Operations hit 8627000.0 in Q4 2025 for Beta Bionics, up from 8729000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 8627000.0 in Q4 2025 to a low of 19975000.0 in Q1 2025.